Beacon Capital Management LLC has recently announced that it has increased stake in Evaxion Biotech A/S ADR (NASDAQ:EVAX) by 606.77%. After grabbing 48633.0 shares, the institutional investor is now in possession of 41752.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.18% having worth around $33362.0. Moreover, AE Wealth Management LLC increased its share by 48633.0 to have a control over 48633.0 shares. And Two Sigma Securities LLC raised its holdings to 15188.0 shares by acquiring 15188.0 shares or 0.06% of the stake.
Evaxion Biotech A/S ADR (EVAX) concluded trading on Wednesday at a closing price of $10.65, with 32.07 million shares of worth about $341.5 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -14.80% during that period and On Wednesday, January 24 the price saw a gain of about 113.43%. Currently the company’s common shares owned by public are about 2.41M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stock saw a price change of 38.98% in past 5 days and over the past one month there was a price change of 54.62%. Year-to-date (YTD), EVAX shares are showing a performance of 55.32% which decreased to -34.66% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.36 but also hit the highest price of $21.10 during that period. The average intraday trading volume for Evaxion Biotech A/S ADR shares is 33.85K. The stock is currently trading 50.81% above its 20-day simple moving average (SMA20), while that difference is up 48.11% for SMA50 and it goes to 2.52% higher than SMA200.
Beacon Capital Management LLC acquired 48633.0 shares of Evaxion Biotech A/S ADR having value of about $33362.0. Data submitted at the U.S SEC by Beacon Capital Management LLC revealed that the firm now holds 41752.0 shares in the company valued at close to $444658.8, or have control over 606.77% stake in the company. Evaxion Biotech A/S ADR (NASDAQ: EVAX) currently have 2.41M outstanding shares and institutions hold larger chunk of about 0.63% of that. Holding of mutual funds in the company is about 0.01% while other institutional holders and individual stake holders have control over 0.62% and — of the stake respectively.
The stock has a current market capitalization of $29.39M and its 3Y-monthly beta is at 0.02. It has posted earnings per share of -$9.44 in the same period. It has Quick Ratio of 2.81. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EVAX, volatility over the week remained 42.41% while standing at 17.17% over the month.
Analysts are in expectations that Evaxion Biotech A/S ADR (EVAX) stock would likely to be making an EPS of -$1.6 in the current quarter, while forecast for next quarter EPS is $0 and it is -$3.75 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.6 which is -$1.6 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.29 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 16.84% while it is estimated to increase by 53.99% in next year.
